Novel Oral Agent for ESR1-Mutated Breast Cancer Boosts PFS in Second-Line

(MedPage Today) — CHICAGO — The investigational oral agent vepdegestrant more than doubled median progression-free survival (PFS) versus fulvestrant (Faslodex) in previously treated estrogen receptor (ER)-positive metastatic breast cancer patients…

Source link : https://www.medpagetoday.com/meetingcoverage/asco/115827

Author :

Publish date : 2025-05-31 12:00:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30	31

Novel Oral Agent for ESR1-Mutated Breast Cancer Boosts PFS in Second-Line

The Covid Inquiry Podcast: ‘I wasn’t the decision maker’

Sacituzumab or Chemo in First-Line TNBC: Which Is Better?

Related Posts

Consider Psychologic Evaluation for Children With Urinary Incontinence

Some Hormone Therapies Linked to Young-Onset Breast Cancer

A crucial methane-tracking satellite has died in orbit

ACIP Members Show Inexperience, Lack of Understanding at First Meeting, Experts Say

Senate Passes Trump’s Tax Bill With $1 Trillion in Health Cuts

HHS Confirms Contracts With Springer Nature Have Been Terminated

Consider Psychologic Evaluation for Children With Urinary Incontinence

Some Hormone Therapies Linked to Young-Onset Breast Cancer

A crucial methane-tracking satellite has died in orbit

ACIP Members Show Inexperience, Lack of Understanding at First Meeting, Experts Say

Senate Passes Trump’s Tax Bill With $1 Trillion in Health Cuts

HHS Confirms Contracts With Springer Nature Have Been Terminated

DREAMM-20 Hints at a More Tolerable Path for BCMA-Targeted Therapy in Myeloma

Sleep and Alzheimer’s; NIH Cuts to Brain Research; Novel CTE Report

Categories

Archives